2 results
Approved WMORecruiting
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
Approved WMOCompleted
The main objective:- To assess the PD properties of a single subcutaneous injection of RUC-4 in STEMI patients presenting to the CCL with the aim to perform primarycoronary angioplasty.- To assess the PK properties of a single subcutaneous injection…